Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Antibodies, Monoclonal, Humanized
Triple Negative Breast Neoplasms
Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).